NCT06851767
Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy
StatusEnrolling by Invitation
PhasePhase 1/2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 69 versions: 40 with changes below, 10 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Interventions modified
- Notable Eligibility criteria shortened, about 18 words
- Secondary endpoints: details revised at 1 of 5 entries
- Study description expanded, about 13 words
- Notable Eligibility criteria expanded, about 112 wordsv65
- Minor Eligibility criteria revisedv56
- Study Status, Study Descriptionv55
Show 35 earlier versionsHide 35 earlier versions
- Minor Start date changed from estimate of May 21, 2025 to May 9, 2025v54
- Minor Start date: May 20, 2025 to May 21, 2025v53
- Minor Start date: May 19, 2025 to May 20, 2025v52
- Minor Start date: May 16, 2025 to May 19, 2025v51
- Minor Start date: May 15, 2025 to May 16, 2025v50
- Minor Start date: May 14, 2025 to May 15, 2025v49
- Minor Start date: May 13, 2025 to May 14, 2025v48
- Minor Start date: May 12, 2025 to May 13, 2025v47
- Minor Start date: May 11, 2025 to May 12, 2025v46
- Minor Start date: May 8, 2025 to May 11, 2025v45
- Minor Start date: May 7, 2025 to May 8, 2025v44
- Notable Trial status: Not Yet Recruiting to Enrolling by Invitation
- Start date: May 6, 2025 to May 7, 2025
- Minor Start date: May 5, 2025 to May 6, 2025v42
- Minor Start date: May 4, 2025 to May 5, 2025v41
- Minor Start date: May 1, 2025 to May 4, 2025v40
- Minor Start date: Apr 30, 2025 to May 1, 2025v39
- Minor Start date: Apr 29, 2025 to Apr 30, 2025v38
- Minor Start date: Apr 28, 2025 to Apr 29, 2025v37
- Minor Start date: Apr 27, 2025 to Apr 28, 2025v36
- Minor Start date: Apr 24, 2025 to Apr 27, 2025v35
- Minor Start date: Apr 23, 2025 to Apr 24, 2025v34
- Minor Start date: Apr 22, 2025 to Apr 23, 2025v33
- Minor Start date: Apr 21, 2025 to Apr 22, 2025v32
- Minor Start date: Apr 20, 2025 to Apr 21, 2025v31
- Notable Primary and study completion dates: Dec 31, 2032 to Dec 31, 2034
- Start date: Apr 16, 2025 to Apr 20, 2025
- Minor Start date: Apr 15, 2025 to Apr 16, 2025v29
- Minor Start date: Apr 13, 2025 to Apr 15, 2025v28
- Minor Start date: Apr 10, 2025 to Apr 13, 2025v27
- Minor Start date: Apr 9, 2025 to Apr 10, 2025v26
- Minor Start date: Apr 8, 2025 to Apr 9, 2025v25
- Minor Start date: Apr 7, 2025 to Apr 8, 2025v24
- Minor Start date: Apr 4, 2025 to Apr 7, 2025v23
- Minor Start date: Apr 3, 2025 to Apr 4, 2025v22
- Minor Start date: Apr 1, 2025 to Apr 3, 2025v21
- Minor Start date: Mar 31, 2025 to Apr 1, 2025v20
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Quantify frequency and severity of adverse events (AEs) related to study agent from infusion to 12 months after infusion.
Timeframe: 12 months
Secondary (5)
Evaluate percentage of participants with >= 5% mutation-repaired alleles in PBMCs.
Evaluate editing efficiency in peripheral blood cells (such as T, B, and natural killer [NK] cells).
Evaluate Immune reconstitution: a. T, B, and NK cell number improvement from baseline. b. Emergence of naive T cells and CD31+ recent thymic emigrants.c. B-cell function: immunoglobulin (Ig) production. d. Specific responses to vacci...
Evaluate clinical efficacy by improvement from baseline problems such as recurrent infection, chronic norovirus, protein-losing enteropathy, gastrointestinal complaints, growth failure, malnutrition, or immune dysregulation.
Evaluate frequency and severity of all study agent-related AEs and serious adverse events (SAEs) from time of study product infusion.
Arms and interventions
Single Arm StudyExperimental
Biologicals: Base-edited hematopoietic stem and progenitor cells
Drugs: Busulfan, Palifermin, Filgrastim, Plerixafor, Campath
Sites
1 site in 1 country
- National Institutes of Health Clinical CenterBethesda, Maryland, United States